Bank Pictet & Cie Europe AG Invests $669,000 in Qiagen N.V. (NYSE:QGEN)

Bank Pictet & Cie Europe AG purchased a new position in Qiagen N.V. (NYSE:QGEN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,899 shares of the company's stock, valued at approximately $669,000.

Other institutional investors have also bought and sold shares of the company. Brown Brothers Harriman & Co. acquired a new stake in Qiagen during the fourth quarter worth about $37,000. EverSource Wealth Advisors LLC boosted its holdings in Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after purchasing an additional 526 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Qiagen by 148.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after buying an additional 835 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Qiagen by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after buying an additional 2,204 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after buying an additional 1,425 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on QGEN shares. Robert W. Baird increased their price objective on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Finally, Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Seven investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Qiagen currently has an average rating of "Hold" and a consensus price target of $47.74.

Qiagen Trading Up 0.4%

Shares of QGEN stock traded up $0.17 on Friday, hitting $46.72. The stock had a trading volume of 2,124,304 shares, compared to its average volume of 1,190,880. The company's 50 day moving average price is $43.50 and its 200-day moving average price is $42.34. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $49.30. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83. The firm has a market capitalization of $10.39 billion, a P/E ratio of 117.14, a P/E/G ratio of 2.37 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. Qiagen's revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.44 EPS. Analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.